Open AccessOcrelizumab associated late-onset neutropenia in the patient with multiple sclerosis: Case report and literature review
Author(s) -
Vanja Jovičević,
Jelena Bila,
Šarlota Mesaroš,
Tatjana Pekmezović,
Jelena Drulović
Publication year - 2022
Publication title -
srpski arhiv za celokupno lekarstvo
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.135
H-Index - 17
eISSN - 2406-0895
pISSN - 0370-8179
DOI - 10.2298/sarh211216042j
Subject(s) - medicine , ocrelizumab , neutropenia , asymptomatic , multiple sclerosis , neurology , cladribine , rituximab , adverse effect , pediatrics , immunology , chemotherapy , antibody , psychiatry
Introduction. Ocrelizumab is a recombinant humanized monoclonal antibody that selectively depletes CD20-expressing B cells, which is approved for the treatment of the relapsing and primary progressive multiple sclerosis (MS). It is extremely rarely associated with late onset neutropenia (LON), as an adverse event. Case Outline. We describe a case, from the Treatment Registry of the Clinic of Neurology, University Clinical Center of Serbia, Belgrade, of a transient, asymptomatic, LON which was detected in a na?ve relapsing-remitting MS patient, six-months after treatment with ocrelizumab. Conclusion. Having in mind all until now available data, which indicate that rarely occurring LON on ocrelizumab is asymptomatic and transient in the majority of cases, we assume that it may be suggested that only in patients with complaints suggesting the presence of possible infection, additional complete blood count monitoring, should be mandatory, exclusively at that moment, apart from the precisely defined regular follow-up.